Press Release: MapmyGenome Launches Babymap Carrier and Newborn Screening
Hyderabad, May 17, 2016
MapmyGenome India launched a carrier and newborn screening test called Babymap™ on May 16, 2016. Recommended for newborns, expecting parents, and people planning a pregnancy, this test screens for 71+ metabolic conditions that can be treated in newborns.
“Pregnancy and parenthood are among the most joyful experiences in a person’s life. We want to make these experiences healthy and tension-free. Babymap allows parents to make informed choices to ensure their newborns and future children stay healthy.” — Anu Acharya, CEO, MapmyGenome
Dr. Radha Rama Devi, MD (Peds) at Rainbow Hospital, who was instrumental in setting up the first Newborn Screening for preventable causes of mental retardation in India, said: “Babymap is an excellent idea and will replace the newborn screening tests currently used.”
The Babymap test requires blood samples for genetic testing using Next Generation Sequencing for over 31,000 pathogenic single nucleotide variants and minor insertions and deletions. Following analysis, a session with MapmyGenome genetic counsellors allows parents to learn about their carrier status and future course of action.
About MapmyGenome
MapmyGenome India Ltd. is a molecular diagnostics company for people who are proactive about their health. They offer personalised health solutions based on genetic tests that help people get to know about themselves. By combining genetic health profile and health history with genetic counselling, MapmyGenome provides actionable steps for individuals and their physicians towards a healthier life.
Founded in January 2013, MapmyGenome started as India’s pioneering Personal Genomics Company with a vision to “Touch 100 million lives and save a million lives by 2030.”
Plan Your Family’s Health from Day One
MapmyGenome offers Babymap carrier and newborn screening, preconception genetic counselling, and NIPT — helping families make informed decisions at every stage of the parenthood journey.
